UZH Life Sciences Fund
VC Fund
Zürich, Switzerland
UZH Life Sciences Fund is a VC fund in Zürich focused on Health Care and Biotechnology. The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries UZH Life Sciences Fund invests in
Stages UZH Life Sciences Fund invests in
Countries UZH Life Sciences Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1M–$1.2M
- Convertible Note
- $1M–$1.1M
Investment Focus
Industry
- Health Care 4 (67%)
- Biotechnology 4 (67%)
- Medical 2 (33%)
- Medical Device 2 (33%)
- Beauty 1 (17%)
Stage
- Seed 2 (33%)
- Convertible Note 2 (33%)
- Venture - Series Unknown 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michio Painter
Board Secretary
|
Board Secretary | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment. | $1.2M / Seed / May 06, 2025 | ||
| FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | $1.1M / Convertible Note / Feb 28, 2024 | ||
| Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $1M / Convertible Note / Aug 29, 2022 | ||
| Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects. | Venture - Series Unknown / Jan 01, 2019 | ||
| ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | Venture - Series Unknown / Oct 01, 2018 | ||
| CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $1M / Seed / Aug 30, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does UZH Life Sciences Fund invest in?
UZH Life Sciences Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Convertible Note stage. Most of the 6 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does UZH Life Sciences Fund invest in?
UZH Life Sciences Fund typically joins rounds of $1M–$1.2M at Seed and $1M–$1.1M at Convertible Note. These are whole funding-round sizes, not UZH Life Sciences Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds UZH Life Sciences Fund took part in.
How do I contact UZH Life Sciences Fund?
Public channels for UZH Life Sciences Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at UZH Life Sciences Fund?
The team at UZH Life Sciences Fund includes Michio Painter (Board Secretary). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
